Abstract
Since September 1996, 48 untreated patients with bulky or advanced-stage Hodgkin's disease received the 12-week Stanford V chemotherapy regimen followed by consolidation radiotherapy at a dose of 36 Gy to bulky mediastinal disease and 30.6 Gy to the initial sites of disease ≥3 cm in transverse diameter. After the combined therapy, 46 of 48 (96%) achieved complete remissions. With a median follow-up of 48 months, the 5-year overall survival was 95% and freedom from progression 86%. There were no treatment-related deaths. All but one premenopausal female patient (who received pelvic and inguinal irradiation) recovered normal menses. Until now no case of secondary leukemia or myelodysplasia was observed. Our results confirm that the Stanford V regimen with consolidation radiotherapy is safe and effective in patients with bulky or advanced-stage Hodgkin's disease, achieving very high remission and overall 5-year survival rates. Longer follow-up is necessary to evaluate the extent of all complications.
| Original language | English |
|---|---|
| Pages (from-to) | 141-147 |
| Number of pages | 7 |
| Journal | Acta Haematologica |
| Volume | 112 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2004 |
Fingerprint
Keywords
- Advanced stages
- Combined modality therapy
- Hodgkin's disease
ASJC Scopus subject areas
- Hematology
Cite this
Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. / Aversa, Savina M L; Salvagno, Luigi; Sorarù, Mariella; Mazzarotto, Renzo; Boso, Caterina; Gaion, Fernando; Chiarion-Sileni, Vanna; De Franchis, Giuseppe; Favaretto, Adolfo G.; Crivellari, Gino; Banna, Giuseppe Luigi; Sotti, Guido; Monfardini, Silvio.
In: Acta Haematologica, Vol. 112, No. 3, 2004, p. 141-147.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease
AU - Aversa, Savina M L
AU - Salvagno, Luigi
AU - Sorarù, Mariella
AU - Mazzarotto, Renzo
AU - Boso, Caterina
AU - Gaion, Fernando
AU - Chiarion-Sileni, Vanna
AU - De Franchis, Giuseppe
AU - Favaretto, Adolfo G.
AU - Crivellari, Gino
AU - Banna, Giuseppe Luigi
AU - Sotti, Guido
AU - Monfardini, Silvio
PY - 2004
Y1 - 2004
N2 - Since September 1996, 48 untreated patients with bulky or advanced-stage Hodgkin's disease received the 12-week Stanford V chemotherapy regimen followed by consolidation radiotherapy at a dose of 36 Gy to bulky mediastinal disease and 30.6 Gy to the initial sites of disease ≥3 cm in transverse diameter. After the combined therapy, 46 of 48 (96%) achieved complete remissions. With a median follow-up of 48 months, the 5-year overall survival was 95% and freedom from progression 86%. There were no treatment-related deaths. All but one premenopausal female patient (who received pelvic and inguinal irradiation) recovered normal menses. Until now no case of secondary leukemia or myelodysplasia was observed. Our results confirm that the Stanford V regimen with consolidation radiotherapy is safe and effective in patients with bulky or advanced-stage Hodgkin's disease, achieving very high remission and overall 5-year survival rates. Longer follow-up is necessary to evaluate the extent of all complications.
AB - Since September 1996, 48 untreated patients with bulky or advanced-stage Hodgkin's disease received the 12-week Stanford V chemotherapy regimen followed by consolidation radiotherapy at a dose of 36 Gy to bulky mediastinal disease and 30.6 Gy to the initial sites of disease ≥3 cm in transverse diameter. After the combined therapy, 46 of 48 (96%) achieved complete remissions. With a median follow-up of 48 months, the 5-year overall survival was 95% and freedom from progression 86%. There were no treatment-related deaths. All but one premenopausal female patient (who received pelvic and inguinal irradiation) recovered normal menses. Until now no case of secondary leukemia or myelodysplasia was observed. Our results confirm that the Stanford V regimen with consolidation radiotherapy is safe and effective in patients with bulky or advanced-stage Hodgkin's disease, achieving very high remission and overall 5-year survival rates. Longer follow-up is necessary to evaluate the extent of all complications.
KW - Advanced stages
KW - Combined modality therapy
KW - Hodgkin's disease
UR - http://www.scopus.com/inward/record.url?scp=4644225088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4644225088&partnerID=8YFLogxK
U2 - 10.1159/000079725
DO - 10.1159/000079725
M3 - Article
VL - 112
SP - 141
EP - 147
JO - Acta Haematologica
JF - Acta Haematologica
SN - 0001-5792
IS - 3
ER -